Citas bibligráficas
Salazar, F., Valdez, V. (2022). Systemic Immune-Inflammation Index and Survival Outcomes in Testicular Cancer: a Systematic Review and Meta-Analysis [Tesis, Universidad Peruana de Ciencias Aplicadas (UPC)]. http://hdl.handle.net/10757/667350
Salazar, F., Valdez, V. Systemic Immune-Inflammation Index and Survival Outcomes in Testicular Cancer: a Systematic Review and Meta-Analysis [Tesis]. PE: Universidad Peruana de Ciencias Aplicadas (UPC); 2022. http://hdl.handle.net/10757/667350
@misc{renati/404245,
title = "Systemic Immune-Inflammation Index and Survival Outcomes in Testicular Cancer: a Systematic Review and Meta-Analysis",
author = "Valdez Cornejo, Valeria Alejandra",
publisher = "Universidad Peruana de Ciencias Aplicadas (UPC)",
year = "2022"
}
Systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with Overall Survival (OS) and Progression-Free Survival (PFS) in testicular cancer. We searched observational studies in 5 databases. A random-effects model was employed for the quantitative synthesis. The Newcastle Ottawa Scale (NOS) was used to evaluate the bias risk. The only measure of effect was Hazard Ratio (HR). The risk of bias in the research was taken into consideration while doing a sensitivity analysis.. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR=3.28; 95% CI 1.3-8.9; P < 0.001; I2= 78) and PFS (HR=3.9; 95% CI 2.53-6.02; P < 0.001; I2= 0). There was no evidence of small study effects in the relationship between SIII levels and OS (p=0.5301). High SIII values are associated with worse OS and PFS.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons